Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.
5. How PARP Inhibitors Work in Women
In this piece from our latest Women’s Cancers issue, learn how these targeted therapies fight disease by stopping the fix-it process in damaged cancer cells.
4. Living with Peace of Mind as a Two-Time Cancer Survivor
Here, a two-time cancer survivor shares how taking action led her doctors to catch an aggressive second cancer.
3. How Can Cancer Survivors Survive COVID-19?
A cancer survivor herself, Barbara Tako wonders what other survivors can do to cope and process the scale of the COVID-19 pandemic in this CURE® Voices piece.
2. Five FDA Approvals You May Have Missed
Despite the challenges posed by the COVID-19 pandemic, the Food and Drug Administration remains committed to expediting oncology drug development. Take a look at five important cancer-related approvals from the past month.
1. Why People with Cancer are My Guides During a Global Pandemic
Here, one person wonders if people with cancer have been emotionally and spiritually prepared for a global pandemic, like what we are experiencing, better than anyone — even better than herself, a social worker in an outpatient clinical oncology unit.
Thank you for reading!
Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story
December 8th 2022After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Listen
Adding a Novel Agent to Standard of Care May Improve Survival in Liver Cancer
October 13th 2023Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.
Read More